
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ONC | Toronto | CAD | Real-time | |
ONCY | NASDAQ | USD | Real-time | |
ONC | CBOE Canada | CAD | Real-time |
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Name | Age | Since | Title |
---|---|---|---|
Wayne F. Pisano | 69 | 2013 | Interim CEO & Chairman of the Board |
Angela Frances Holtham | 73 | 2014 | Independent Director |
Bernd Robert Seizinger | 68 | 2015 | Independent Director |
Deborah M. Brown | - | 2017 | Independent Director |
Martine Piccart | - | 2017 | Member of Scientific Advisory Board |
Jonathan M. N. Rigby | 56 | 2022 | Independent Director |
Padmanee Sharma | - | - | Member of Scientific Advisory Board |
James T. Parsons | 59 | 2022 | Independent Director |
Richard Vile | - | 2020 | Member of Scientific Advisory Board |
Patricia S. Andrews | 65 | 2024 | Independent Director |
Dirk Arnold | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review